GeoVax Labs And 2 Other Stocks Under $2 Insiders Are Buying
Portfolio Pulse from Avi Kapoor
Insiders at Perspective Therapeutics, VerifyMe, and GeoVax Labs have recently made notable stock purchases. Perspective Therapeutics Director Robert F. Williamson III bought shares following the divestiture of its brachytherapy business. VerifyMe's CEO Adam Stedham purchased shares after the board approved a share repurchase program. GeoVax Labs' CMO Kelly McKee acquired shares as the company expanded rights under an NIH license for COVID-19, Mpox, and smallpox.
December 27, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Perspective Therapeutics Director Robert F. Williamson III bought 3,663 shares at $0.33 each after the company announced the divestiture of its brachytherapy business.
The insider purchase by a director suggests confidence in the company's future prospects, especially following a strategic divestiture, which could be seen positively by investors.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
GeoVax Labs CMO Kelly McKee bought 6,944 shares at $0.36 each as the company expanded NIH license rights for COVID-19, Mpox, and smallpox.
The insider purchase by the CMO following the expansion of license rights for significant diseases suggests a bullish outlook for the company's vaccine development pipeline.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
VerifyMe CEO Adam Stedham acquired 1,953 shares at $1.04 each after the board approved a share repurchase program of up to $500,000.
The CEO's purchase, coupled with the recent approval of a share repurchase program, indicates a strong positive signal to the market that could lead to a short-term price increase.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80